Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / ATEC - ATEC Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights


ATEC - ATEC Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights

  • Revenue growth of 68% for full year 2021, including organic revenue growth of 50%
  • U.S. organic revenue 3-year CAGR of 36%
  • Fourth quarter EOS imaging-related revenue of $12.8 million

Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter and full year ended December 31, 2021, and recent corporate highlights.

Fourth Quarter and Full Year 2021 Financial Results

Quarter Ended
December 31, 2021

Year Ended
December 31, 2021

Total revenue

$74.0 million

$243.2 million

GAAP gross margin

61.1%

64.9%

Non-GAAP gross margin

70.5%

72.8%

Operating expenses

$83.4 million

$285.8 million

Non-GAAP operating expenses

$66.2 million

$225.6 million

GAAP operating loss

($38.1) million

($128.1) million

Non-GAAP adjusted EBITDA

($7.5) million

($28.1) million

Ending cash balance

$187.2 million

Recent Highlights

  • Accelerated adoption of Prone Trans-Psoas (PTP) Technique, with ATEC lateral procedures delivering over 40% of Q4 revenue growth;
  • Expanded momentum of the recently launched ALIF System advancing anterior column prowess;
  • Trained over 400 surgeons in 2021, contributing to a 23% increase in surgeon users in Q4 compared to prior year;
  • Generated $12.8 million in EOS-related revenue, with significant momentum in sales, product development and data management since close of transaction.

“2021 marks the highest revenue on record for ATEC and another year of sector-leading growth,” remarked Pat Miles, Chairman and Chief Executive Officer. “The magnitude and consistency of our growth is a direct reflection of our ability to earn surgeon trust. That trust is a result of our relentless commitment to creating clinically distinct technology that improves the predictability and reproducibility of spine surgery. In 2022, we will continue to expand the lateral market with PTP, advance our distribution network, and place EOS imaging systems while driving portfolio-wide adoption. ATEC is becoming a force in the spine industry.”

Financial Outlook for the Full Year 2022

The Company continues to expect total revenue for the fiscal year ended December 31, 2022, to approximate $305 million, reflecting growth of approximately 25% compared to the full year 2021. This includes organic revenue growth of 23% and approximately $45 million of revenue related to EOS imaging.

Investor Webcast

ATEC will present these results via a live webcast today at 1:30 p.m. PT / 4:30 p.m. ET. The live webcast can be accessed by visiting the Investor Relations Section of ATEC’s Corporate Website.

To dial-in to the webcast, please register via this link .

A replay of the webcast will remain available through the Investor Relations section of ATEC’s Corporate Website at investors.alphatecspine.com for twelve months. In addition, a dial-in replay will be available beginning two hours after the webcast’s completion until March 8, 2022. The replay dial-in numbers are (800) 585-8367 for domestic callers and (416) 621-4642 for international callers. Please use the replay conference ID number 6548679.

Non-GAAP Financial Information

To supplement the Company’s financial statements presented in accordance with generally accepted accounting principles in the United States of America (GAAP), the Company reports certain non-GAAP financial measures, including non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating loss, and non-GAAP adjusted EBITDA. The Company believes that these non-GAAP financial measures provide investors with an additional tool for evaluating the Company's core performance, which management uses in its own evaluation of continuing operating performance, and a baseline for assessing the future earnings potential of the Company. The Company’s non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company’s industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. Non-GAAP financial results should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Included below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.

About Alphatec Holdings, Inc.

ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation Machine™ is focused on developing new approaches that integrate seamlessly with the Company’s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC’s vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com .

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company’s revenue and growth outlook; planned product launches, introductions, regulatory submissions or clearances; efforts to transform sales and distribution channels; the Company’s ability to compel surgeon adoption; the Company’s future ability to finance its operations and sufficiency of its cash runway; and statements about the potential benefits and synergies of the acquisition of EOS imaging, S.A. Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the Company’s ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company’s products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third-party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company’s ability to achieve profitability; uncertainty of additional funding; the Company’s ability to compete with other products or with emerging technologies; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company’s intellectual property; the Company’s ability to meet its financial obligations; the impact of the COVID-19 pandemic on the Company and economy; and uncertainties and risks related to the integration of EOS imaging, S.A. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

ALPHATEC HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three Months Ended

Year Ended

December 31,

December 31,

2021

2020

2021

2020

unaudited

Revenue:
Revenue from products and services

$

73,922

$

43,123

$

242,258

$

141,079

Revenue from international supply agreement

40

831

954

3,782

Total revenue

73,962

43,954

243,212

144,861

Cost of sales

28,737

12,563

85,450

42,360

Gross profit

45,225

31,391

157,762

102,501

Operating expenses:
Research and development

8,984

5,355

32,015

18,745

Sales, general and administrative

66,692

39,725

229,271

129,156

Litigation-related expenses

5,412

3,045

11,123

8,552

Amortization of acquired intangible assets

1,956

172

5,348

688

Transaction-related expenses

209

130

6,365

4,223

Restructuring expenses

110

1,697

Total operating expenses

83,363

48,427

285,819

161,364

Operating loss

(38,138

)

(17,036

)

(128,057

)

(58,863

)

Interest and other expense, net:
Interest expense, net

(1,504

)

(3,700

)

(7,108

)

(12,374

)

Loss on debt extinguishment, net

(6,057

)

(7,434

)

(7,612

)

Other expenses, net

(544

)

(1,563

)

Total interest and other expenses, net

(2,048

)

(9,757

)

(16,105

)

(19,986

)

Net loss before taxes

(40,186

)

(26,793

)

(144,162

)

(78,849

)

Income tax provision

1

5

164

145

Net loss

$

(40,187

)

$

(26,798

)

$

(144,326

)

$

(78,994

)

Net loss per share, basic and diluted

$

(0.40

)

$

(0.35

)

$

(1.50

)

$

(1.18

)

Weighted average shares outstanding, basic and diluted

99,300

77,098

96,197

67,020

Stock-based compensation included in:
Cost of revenue

$

248

$

138

$

737

$

512

Research and development

1,454

632

4,056

2,114

Sales, general and administrative

8,024

4,202

31,657

15,033

$

9,726

$

4,972

$

36,450

$

17,659

ALPHATEC HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

December 31, 2021

December 31, 2020

ASSETS

Current assets:
Cash and cash equivalents

$

187,248

$

107,765

Accounts receivable, net

41,893

23,527

Inventories

91,703

46,001

Prepaid expenses and other current assets

10,313

5,439

Withholding tax receivable from Officer

1,076

Current assets of discontinued operations

352

Total current assets

331,157

184,160

Property and equipment, net

87,401

36,670

Right-of-use asset

25,283

1,177

Goodwill

39,689

13,897

Intangible assets, net

85,274

24,720

Other assets

3,249

541

Noncurrent assets of discontinued operations

58

Total assets

$

572,053

$

261,223

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable

$

25,737

$

17,599

Accrued expenses and other current liabilities

55,549

35,264

Contract liability

15,255

Short-term debt

342

4,167

Current portion of operating lease liability

4,212

885

Current liabilities of discontinued operations

397

Total current liabilities

101,095

58,312

Total long-term liabilities

367,933

49,428

Redeemable preferred stock

23,603

23,603

Stockholders' equity

79,422

129,880

Total liabilities and stockholders' equity

$

572,053

$

261,223

ALPHATEC HOLDINGS, INC.

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(in thousands)

Three Months Ended

Year Ended

December 30,

December 30,

2021

2020

2021

2020

unaudited
Gross profit, GAAP

$

45,225

$

31,391

$

157,762

$

102,501

Add: amortization of intangible assets

268

269

1,075

1,075

Add: stock-based compensation

248

138

737

512

Add: purchase accounting adjustments on acquisitions

2,083

6,423

Add: excess and obsolete write-down

4,305

1,615

11,147

7,044

Non-GAAP gross profit

$

52,129

$

33,413

$

177,144

$

111,132

Gross margin, GAAP

61.1

%

71.4

%

64.9

%

70.8

%

Add: amortization of intangible assets

0.4

%

0.6

%

0.4

%

0.7

%

Add: stock-based compensation

0.3

%

0.3

%

0.3

%

0.4

%

Add: purchase accounting adjustments on acquisitions

2.8

%

0

%

2.6

%

0.0

%

Add: excess and obsolete write-down

5.8

%

3.7

%

4.6

%

4.9

%

Non-GAAP gross margin

70.5

%

76.0

%

72.8

%

76.7

%

Three Months Ended

Year Ended

December 30,

December 30,

2021

2020

2021

2020

unaudited
Operating expenses, GAAP

$

83,363

$

48,427

$

285,819

$

161,364

Adjustments:
Stock-based compensation

(9,478

)

(4,834

)

(35,713

)

(17,147

)

Litigation-related expenses

(5,412

)

(3,045

)

(11,123

)

(8,552

)

Amortization of intangible assets

(1,956

)

(172

)

(5,348

)

(688

)

Transaction-related expenses

(209

)

(130

)

(6,365

)

(4,223

)

Restructuring expenses

(110

)

(1,697

)

Non-GAAP operating expenses

$

66,198

$

40,246

$

225,573

$

130,754

Three Months Ended

Year Ended

December 30,

December 30,

2021

2020

2021

2020

unaudited
Operating loss, GAAP

$

(38,138

)

$

(17,036

)

$

(128,057

)

$

(58,863

)

Depreciation

6,544

2,704

20,332

9,186

Amortization of intangible assets

2,226

441

6,424

1,763

EBITDA

(29,368

)

(13,891

)

(101,301

)

(47,914

)

Add back significant items:
Stock-based compensation

9,726

4,972

36,450

17,659

Purchase accounting adjustments on acquisitions

2,083

6,423

Excess & obsolete write-down

4,305

1,615

11,147

7,044

Litigation-related expenses

5,412

3,045

11,123

8,552

Transaction-related expenses

209

130

6,365

4,223

Restructuring expenses

110

1,697

Adjusted EBITDA

$

(7,523

)

$

(4,129

)

$

(28,096

)

$

(10,436

)

View source version on businesswire.com: https://www.businesswire.com/news/home/20220301005574/en/

Investor/Media Contact:
Tina Jacobsen, CFA
Investor Relations
(760) 494-6790
investorrelations@atecspine.com

Company Contact:
J. Todd Koning
Chief Financial Officer
investorrelations@atecspine.com

Stock Information

Company Name: Alphatec Holdings Inc.
Stock Symbol: ATEC
Market: NASDAQ
Website: atecspine.com

Menu

ATEC ATEC Quote ATEC Short ATEC News ATEC Articles ATEC Message Board
Get ATEC Alerts

News, Short Squeeze, Breakout and More Instantly...